entertainment -WSS

entertainment

author：Wikipedia 2025-09-06 01:55:38 - browse：25726

Purple AML cells in blood flow — coverage from STAT — Acute myeloid leukemia cells amid blood flow. Adobe

The Food and Drug Administration issued a change to the warning label for Legend Biotech and Janssen’s myeloma CAR-T, Carvykti or cilta-cel, adding that some secondary blood cancers have occurred following treatment for multiple myeloma with the cell therapy.

While the label means that physicians will have to have a conversation about secondary malignancies occurring after Carvykti treatment, oncologists and CAR-T experts said the label update won’t change anything about the use of Carvykti.

“I do not believe this particular change will have any bearing on patient care,” said Saad Usmani, a myeloma physician and cell therapist at Memorial Sloan Kettering who has also studied Carvykti. That’s partly because physicians already discuss the risk of second cancers due to other cancer therapies including radiation, some targeted therapies, and some chemotherapies, which are necessary in the use of CAR-T. “We do have secondary primary malignancy discussions with patients in the context of transplant and will have to do for CAR-T as well,” Usmani said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Diverse clinical trials: Why aren’t we there yet?

knowledge

explore

WSS

Food makers to regulators: Ultra

The strange history of BMI, the body mass index

Food makers to regulators: Ultra

Popular nasal decongestant doesn't actually relieve congestion

The strange history of BMI, the body mass index

The simple reason for the increase in autism diagnosis

hotspot

entertainment

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Federal board approves $12.7 billion budget for Puerto Rico as island shakes off bankruptcy

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

GOP inquiry over gain

Peter Hotez and the public health issue of online harassment

ADA: All diabetes patients should be screened for liver condition

Medicare details structure of new drug price negotiation program

How medical schools plan to diversify without affirmative action

Dobbs anniversary: the lost opportunity of abortion as health care

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

focus

WATCH: Why do bright lights make us see spots?

Diverse clinical trials: Why aren’t we there yet?

The simple reason for the increase in autism diagnosis

Federal board approves $12.7 billion budget for Puerto Rico as island shakes off bankruptcy

Medical experts exlpore how to eliminate bias in clinical algorithms

FDA approves updated Covid vaccines

explore

knowledge

explore

focus